Copernicus Therapeutics, Inc. Receives $1 Million From Cystic Fibrosis Foundation Therapeutics To Advance Development Of A Non-Viral Gene Therapy For Cystic Fibrosis
10/19/2005 5:12:27 PM
CLEVELAND--(BUSINESS WIRE)--Jan. 20, 2005--Copernicus Therapeutics, Inc. today announced that it has received an extension to its therapeutics development award from Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT). This award in the amount of $750,000 was coupled with a $280,000 outstanding payment from the original therapeutics development award to bring the total payment to $1.03 million. The award extension is intended to support the Phase II advancement of Copernicus' potential genetic therapy for cystic fibrosis (CF). Copernicus' unique, non-viral nanoparticle formulation is intended to deliver a normal copy of the CF gene to the affected airway cells of people with CF, and may eventually provide a long-term treatment for this disease.
comments powered by